Alteogen Inc.
196170
Rank in Stocks
#1844
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Share Price
$165.61
Market Cap
$11.53B
Change (1 day)
4.13%
Change (1 year)
-46.48%
Country
KR
Trade Alteogen Inc. (196170)
Category
Healthcare
Revenue for Alteogen Inc. (196170)
Revenue in Jun 2026 TTM: $175.65M
According to Alteogen Inc. latest financial reports the company's current revenue (TTM) is $175.65M. In 2023 the company made a revenue of $74.56M an increase over the revenue in the year 2022 that was $22.83M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Alteogen Inc. from 2012 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $175.65M | 151.07% |
| 2024 | $69.96M | -6.17% |
| 2023 | $74.56M | 226.63% |
| 2022 | $22.83M | -29.96% |
| 2021 | $32.59M | -16.60% |
| 2020 | $39.08M | 54.39% |
| 2019 | $25.31M | 105.68% |
| 2018 | $12.31M | 8.35% |
| 2017 | $11.36M | 100.10% |
| 2016 | $5.68M | 41.12% |
| 2015 | $4.02M | -37.51% |
| 2014 | $6.44M | 22.58% |
| 2013 | $5.25M | 41.14% |
| 2012 | $3.72M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 7,087.26% |
US
|
|
| $2.23B | 1,168.44% |
US
|
|
| $15.74B | 8,863.55% |
AU
|
|
| $6.02B | 3,328.04% |
NL
|
|
| - | - |
CH
|
